The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...

"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...

Obtaining the Marketing Authorisation Application (MAA) is a key step in the commercialization of drugs in the EU, and also an important help to promote the global market expansion of pharmaceutical ...

Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

Its approval has been praised for offering patients more options, particularly those who cannot, or do not want to, undergo chemotherapy. Cabozantinib (also known under the brand name Cabozantinib ...

Two new treatments have been approved for patients in the NHS (Dominic Lipinski/PA) Two new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish ...

SEOUL, March 10 (Yonhap) -- The approval rating for the ruling People Power Party (PPP) rebounded to 42.7 percent, narrowing the gap with the main opposition Democratic Party (DP) to within the margin ...

Two new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines Consortium (SMC) announced it had recommended two treatments for the diseases.

The combination of Opdivo plus Yervoy was granted accelerated approval by the U.S. FDA in 2020 as a second-line treatment for patients with advanced HCC based on Phase 2 CheckMate -040 trial results.